Advanced research and development work is underway into a novel gene therapy employing cutting edge nano technology which, we believe, may have the potential to boost the treatment of several forms of cancer.

Since acquiring the rights to its proprietary, non-insecticide diol technology in the 1990s, EctoPharma has successfully brought this head lice product through all stages of research & development to the point that it is market-ready.

EctoPharma was founded in Scotland in 1994 and is a privately held virtual pharmaceutical and biotechnology company focused on commercialising patented technologies in human and veterinary science.